hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06386783 id: Asw.U./823 /7/23 briefTitle: Fentanyl Versus Dexmedetomidine as an Adjuvant to Bupivacaine in Spinal Anesthesia ; Peritoneal Symptomatic Effects overallStatus: RECRUITING date: 2023-07-01 date: 2024-12-31 date: 2025-07-01 date: 2024-04-26 date: 2024-04-26 name: Aswan University class: OTHER briefSummary: To compare whether 5 μg dexmedetomidine with 25 μg fentanyl added to 0.5% hyperbaric bupivacaine as adjuvants in spinal anaesthesia in patients undergoing appendectomy could reduce intraoperative peritoneal related symptoms. conditions: Dexmedetomidine conditions: Fentanyl studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This randomized double blinded study will be conducted at Aswan university hospitals at patients scheduled for emergency appendectomy primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: concealed based on study drugs assigned to each group \& to conduct this double -blinded clinical trials, our study drugs will be prepared by the senior anesthesiologist who won't be involved in further observations of the patients and neither patients nor outcome assessor will be aware of which drugs they will receive. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 148 type: ESTIMATED name: Dexmedetomidine Injection [Precedex] name: Fentanyl HCl measure: intraoperative peritoneal symptoms during appendectomy. measure: Assessment of motor block with Modified Bromage scale measure: Degree of post-operative analgesia measure: Assessment of sensory block by using pin prick method sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Aswan University status: RECRUITING city: Aswan zip: 81528 country: Egypt name: Soudy S Hammad, MD role: CONTACT phone: +201014761523 email: soudi.salah@aswu.edu.eg name: Ahmed M Hagag, MSc role: CONTACT phone: 01141097536 name: Ayman M Eldemrdash, MD role: PRINCIPAL_INVESTIGATOR name: Ahmed A Mahmoud, MD role: SUB_INVESTIGATOR lat: 24.09082 lon: 32.89942 hasResults: False
nctId: NCT06386770 id: Asw.U./742 /2/23 briefTitle: Systemic Versus Local Dexmedetomidine as An Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Block overallStatus: RECRUITING date: 2023-02-01 date: 2024-06-01 date: 2025-12-31 date: 2024-04-26 date: 2024-04-26 name: Aswan University class: OTHER briefSummary: The aim of this study is to investigate the analgesic effect of local versus systemic dexamedetomedine as adjuvant to bupivacaine in erector spinae block in kidney exploration surgeries. conditions: Erector Spinae Block conditions: Dexmedetomidine studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: These prospective, randomized, controlled clinical trials will be performed in Aswan University Hospital on 75 patients who are scheduled for kidney exploration surgeries primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: In our randomized controlled trial, we employed masking (also called blinding) to reduce bias. Participants were unaware of whether they were receiving the intervention or control. Caregivers were instructed not to reveal this information, and outcome assessors who evaluated results were kept separate from intervention delivery. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 75 type: ESTIMATED name: Dexmedetomidine Injection [Precedex] name: Bupivacaine Hydrochloride name: Dexmedetomidine in 0.9 % NaCl 200 Mcg/50 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML) measure: The duration of analgesia, this was defined as the time in minutes to the first request for postoperative analgesics. measure: 2. Total postoperative opioid consumption (Nalbuphine consumption (mg) within the 48-hour period . measure: Ramsay Sedation Scale (RSS) (1: anxious; 2: cooperative and tranquil; 3: responding to command; 4: brisk response to stimuli; 5: sluggish response to stimuli; and 6: no response to stimuli) will be all assessed measure: Intraoperative hemodynamic parameters blood pressure measure: Minimum alveolar concentration (MAC) requirements sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Aswan University status: RECRUITING city: Aswan zip: 81511 country: Egypt name: soudy S hammad role: CONTACT phone: +201014761523 email: soudi.salah@aswu.edu.eg name: tarek S hemaida role: CONTACT phone: 01007363190 email: dr.tarek@aswu.edu.eg name: Rehab A Mahmoud, MSc role: SUB_INVESTIGATOR lat: 24.09082 lon: 32.89942 hasResults: False
nctId: NCT06386757 id: Asw.U. 911/3/24 briefTitle: Incidence Of Nasal and Oropharyngeal Bleeding: Video Laryngoscopy Versus Direct Laryngoscopy overallStatus: RECRUITING date: 2024-03-01 date: 2025-03-31 date: 2025-12-31 date: 2024-04-26 date: 2024-04-26 name: Aswan University class: OTHER briefSummary: The objective of this study is to compare the effectiveness and safety of video laryngoscopy versus direct laryngoscopy for nasal intubation in patients with maxillofacial fractures regarding less bleeding to oral and nasal structures, quicker intubation times, increased success rates for first intubation attempts, fewer uses of the Magill forceps and the less need for cervical spine extension conditions: Maxillofacial Injuries conditions: Nasal Bleeding conditions: Intubation Complication studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: These prospective, randomized, controlled clinical trials will be conducted at Aswan University Hospital on 62 patients who are scheduled for maxillofacial surgeries requiring nasal intubation. primaryPurpose: PREVENTION masking: NONE count: 64 type: ESTIMATED name: Combined Video Laryngoscopy (VL) and Bougie name: Combined Direct Laryngoscopy (DL) and Bougie measure: Incidence of nasal and oropharyngeal bleeding measure: Time of successful intubation, defined as the time from removal of mask ventilation and beginning of bougie insertion until inflation of tube cuff measure: Overall rate of first trial success. measure: The use of magill forceps sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Aswan University status: RECRUITING city: Aswan zip: 81528 country: Egypt name: Soudy S Hammad, MD role: CONTACT phone: +201014761523 email: soudi.salah@aswu.edu.eg name: Mohammed E Yahia, MSc role: CONTACT phone: 01125257916 name: Mohammed A Alazhary, MD role: SUB_INVESTIGATOR lat: 24.09082 lon: 32.89942 hasResults: False
nctId: NCT06386744 id: DUS-AUBD-01 briefTitle: Dusquetide for the Treatment of Behcet's Disease overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2025-02 date: 2025-03 date: 2024-04-26 date: 2024-04-26 name: Soligenix class: INDUSTRY briefSummary: This is a clinical study to see if dusquetide can treat flares of oral and genital ulcers caused by Behcet's Disease. Study participants will receive an infusion of dusquetide twice a week for 4 weeks (8 treatments total), with weekly follow-up visits for an additional 4 weeks. conditions: Behçet Disease studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 25 type: ESTIMATED name: Dusquetide measure: Number of Oral Ulcers measure: Number of Genital Ulcers measure: Pain of Oral Ulcers measure: Pain of Genital Ulcers sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Istanbul University - Cerrahpasa, Cerrahpasa School of Medicine city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06386731 id: SYNEO-01 briefTitle: Continuous Versus Intermittent Phototherapy in Treatment of Neonatal Jaundice overallStatus: COMPLETED date: 2022-07-05 date: 2022-11-25 date: 2023-04-28 date: 2024-04-26 date: 2024-04-26 name: Goztepe Prof Dr Suleyman Yalcın City Hospital class: OTHER briefSummary: One of the most common diseases in the neonatal period is indirect hyperbilirubinemia (IHB). After phototherapy was discovered accidentally in 1958, it has been used as the most effective treatment method for IHD for more than 60 years. Sources that provide phototherapy are developing rapidly technologically. However, there is no clearly defined usage table in the literature for applying phototherapy with faster effects and fewer side effects. In recent years, the use of intermittent phototherapy has been recommended with similar effectiveness. Phototherapy has significant side effects such as dehydration, diarrhea, chromosome breaks, retinal damage, skin rashes, hypocalcemia, thrombocytopenia. As phototherapy exposure decreases, its side effects decrease.In our study; We plan to find the most ideal method in the treatment of IHB by comparing intermittent PT with continuous phototherapy in terms of effectiveness. We aim to achieve the best bilirubin reduction and minimal side effects with less exposure to phototherapy. conditions: Neonatal Jaundice conditions: Phototherapy Complication studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This was a single-center, with block randomisation \[1:1\], open-label, parallel group study. primaryPurpose: TREATMENT masking: NONE count: 225 type: ACTUAL name: Intermittent Phototherapy measure: Comparison of the effectiveness of CPT and IPT measure: Comparison of side effect frequency of CPT and IPT sex: ALL minimumAge: 1 Day maximumAge: 15 Days stdAges: CHILD facility: Göztepe Prof. Dr. Suleyman Yalcin City Hopital city: Kadıköy state: İstanbul zip: 34730 country: Turkey lat: 40.62015 lon: 29.22536 hasResults: False
nctId: NCT06386718 id: USG for ped art can briefTitle: Ultrasonographic Evaluation of Arteries of the Hand in Pediatric Patients overallStatus: RECRUITING date: 2023-05-15 date: 2024-06-01 date: 2025-05-01 date: 2024-04-26 date: 2024-04-26 name: Ankara University class: OTHER briefSummary: Ultrasound measurements of the ulnar artery and radial artery at different angles are obtained and compared to determine the optimal diameters for possible arterial cannulation in pediatric patients. conditions: Ulnar and Radial Artery studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 184 type: ESTIMATED measure: Determining the Diameter and Depth at different angles measure: Comparing Ulnar and Radial Artery Diameters Across Age Groups sex: ALL maximumAge: 10 Years stdAges: CHILD facility: Ankara University School Of Medicine status: RECRUITING city: Ankara zip: 06100 country: Turkey name: Zeynep Altinbas, MD role: CONTACT phone: +905356082156 email: szpostalcioglu@gmail.com name: Ozlem S Can, MD role: PRINCIPAL_INVESTIGATOR name: Zeynep S Altinbas, MD role: SUB_INVESTIGATOR lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06386705 id: TSN084-101CH briefTitle: A Study of TSN084 in Patients With Advanced Malignant Tumors overallStatus: RECRUITING date: 2022-07-20 date: 2025-09-30 date: 2026-03-30 date: 2024-04-26 date: 2024-04-26 name: Tyligand Bioscience (Shanghai) Limited class: INDUSTRY briefSummary: TSN084 is a novel type II kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This phase 1a/1b study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of TSN084 in advanced or metastatic malignancies in China. conditions: Malignant Neoplasm studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 114 type: ESTIMATED name: TSN084 measure: Dose limiting toxicity (DLT) measure: Incidence of Treatment-Emergent Adverse Events (TEAE) measure: Maximum plasma concentration (Cmax) measure: Time to Cmax (Tmax) measure: Area under the concentration versus time curve from time 0 to the last measurable concentration (AUC 0-t) measure: Objective response rate (ORR) measure: Duration of response (DoR) measure: Disease control rate (DCR) measure: Time to response (TTR) measure: Progression free survival (PFS) measure: Overall survival (OS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cancer Hospital Chinese Academy of Medical Sciences status: RECRUITING city: Beijing state: Beijing zip: 100021 country: China name: Jie Wang, MD, PhD role: CONTACT lat: 39.9075 lon: 116.39723 facility: Peking university cancer hospital status: RECRUITING city: Beijing state: Beijing zip: 100142 country: China name: Minglei Zhuo, MD role: CONTACT lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06386692 id: Aarhus111 briefTitle: Community Based Promotion of Physical Activity in Nepal (COBIN-PA) overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-10-30 date: 2024-12-30 date: 2024-04-26 date: 2024-04-26 name: University of Aarhus class: OTHER briefSummary: Globally, one in four adults does not meet the WHO-recommended level of physical activity. Insufficient physical activity is the fourth leading risk factor, contributing to 9% of global premature mortality. PA is effective in weight management, cardiorespiratory fitness, and increasing quality of life. However, there is lack of evidence on effectiveness on promoting physical activity in community level. The aim of the study is to test the effectiveness of Female Community Health Volunteers (FCHVs)-led community-based educational program on physical activity promotion in community level. This is an open label cluster-randomized controlled trial with 1:1 allocation where FCHVs will deliver a family-based education for the promotion of physical activity at community level in Nepal. The intervention package will be guided by Theory of planned behavior and will contain home-based interactive health education sessions focused on increasing PA in a household setting. FCHVs will use resource materials for health education. The mixed-effect linear regression model will determine the adjusted interaction between time and intervention. The results of this study will show the changes in the mean moderate to vigorous physical activity minutes per day due to time intervention interaction. The evidence generated from this study will help to provide new knowledge on the community-based promotion of Physical Activity and its effectiveness for policymakers and researchers. It will hopefully support the attainment of the national and global target of reducing insufficient physical activity. conditions: Exercise studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 264 type: ESTIMATED name: FCHVs-led community based educational physical activity intervention measure: Mean moderate to vigorous physical activity sex: ALL minimumAge: 19 Years maximumAge: 69 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06386679 id: R016634005 briefTitle: Amniotic Fluid Mesenchymal Stem Cells Developed for Chondrogenic Treatment (AFCC) Injection in Elderly Knee Osteoarthritis Patients overallStatus: ENROLLING_BY_INVITATION date: 2023-08-17 date: 2023-11-23 date: 2025-03 date: 2024-04-26 date: 2024-04-26 name: Siriraj Hospital class: OTHER briefSummary: Amniotic fluid mesenchymal stem cells developed for chondrogenic treatment (AFCC) are used to treat elderly patients suffering from knee osteoarthritis (OA). The injection reduces inflammation and promotes the recovery of knee function, leading to an improved quality of life. conditions: Knee Osteoarthritis studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Ten elderly patients from both gender diagnosed with knee osteoarthritis, will be enrolled according to specific inclusion and exclusion criteria. These patients will be injected with amniotic fluid mesenchymal stem cells developed for chondrogenic treatment. Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee. primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: allogenic amniotic fluid mesenchymal stem cell measure: Incidence of abnormal physical examination measure: Incidence of abnormal vital sign measure: Incidence of abnormal laboratory test results measure: Incidence of abnormal ECG parameters measure: The type of Adverse event (AE), numbers of AE and proportion of patients with AE. measure: Pain score measure: Knee Injury and Osteoarthritis Outcome Score (KOOS) measure: Degree of cartilage change sex: ALL minimumAge: 60 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Siriraj Hospital city: Bangkok Noi state: Bangkok zip: 10700 country: Thailand lat: 13.76266 lon: 100.47798 hasResults: False
nctId: NCT06386666 id: RLRL-CTP briefTitle: A Clinical Trial to Evaluate the Safety and Efficacy of Single-use Fibrous Ring Sutures for the Suture of Fibrous Ring Incision After Nucleus Pulposus Removal overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-04-29 date: 2025-07-15 date: 2024-04-26 date: 2024-04-26 name: Suzhou Kerui Medical Technology Co., Ltd class: OTHER briefSummary: The objective of this clinical trial was to evaluate the safety and effectiveness of single-use annular sutures for the closure of annular incisions after nucleus pulposus removal. Participants used single-use annular sutures to close the annular fibers. The success rate of suture, reduction value of annulus, proportion of annulus reduction, intraoperative blood loss, suture time, VAS pain score (low back, bilateral lower extremities), Oswestry index (ODI index), and Short were evaluated The effectiveness evaluation results of Form-12 health survey (SF-12 score), treatment success rate, device defects, product operation satisfaction, and safety evaluation results of recurrence rate, adverse events, and serious adverse events were used to verify the safety and effectiveness of disposable fibrillar suture for annular incision suture after nucleus pulposus removal. conditions: Intervertebral Disc Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 135 type: ESTIMATED name: Disposable fibrous ring sutures measure: Success rate of suture measure: Annulus fibril cleft decreased in value measure: Reduced proportion of annular fibril cleft measure: Intraoperative blood loss measure: Suture time measure: Treatment success rate measure: VAS pain score (lower back, bilateral lower limbs) measure: SF-12 rating measure: ODI index measure: Recurrence rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06386653 id: [123I]I-DARPIN-Ec1 briefTitle: Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 overallStatus: ENROLLING_BY_INVITATION date: 2024-05-14 date: 2024-12-31 date: 2024-12-31 date: 2024-04-26 date: 2024-04-26 name: Tomsk National Research Medical Center of the Russian Academy of Sciences class: OTHER name: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences name: Uppsala University briefSummary: The study should evaluate the biological distribution of \[123I\]I-DARPIN-Ec1 in patients with lung and ovarian cancer
1. To compare the obtained \[123I\]I-DARPIN-Ec1 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in lung and ovarian cancer patients. conditions: Lung Cancer conditions: Ovarian Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: SINGLE whoMasked: PARTICIPANT count: 10 type: ESTIMATED name: Diagnostic Test: whole body study and SPECT with [123I]I-DARPIN-Ec1 measure: Gamma camera-based whole-body [123I]I-DARPIN-Ec1 uptake value (%) measure: SPECT-based [123I]I-DARPIN-Ec1 value in tumor lesions (counts) measure: SPECT-based [123I]I-DARPIN-Ec1 uptake value (counts) measure: Tumor-to-background ratio (SPECT) measure: Percent of cases with abnormal findings in physical examination, vital signs and ECG associated with [123I]I-DARPIN-Ec1 injections. measure: Percent of cases with abnormal laboratory test results associated with [123I]I-DARPIN-Ec1 injections associated with [123I]I-DARPIN-Ec1 injections. measure: Incidence and severity of adverse events associated with [123I]I-DARPIN-Ec1 injections measure: Percent of cases requiring administration of concomitant medication due to [123I]I-DARPIN-Ec1 injections sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: TomskNRMC city: Tomsk country: Russian Federation lat: 56.49771 lon: 84.97437 hasResults: False
nctId: NCT06386640 id: 0784 briefTitle: A Holistic Patient-centred Intervention to Improve Outcomes of Older People Living With Frailty and Chronic Heart Failure acronym: FIT-HF overallStatus: RECRUITING date: 2023-01-27 date: 2025-04-30 date: 2025-04-30 date: 2024-04-26 date: 2024-04-26 name: University of Leicester class: OTHER briefSummary: Two-centre complex intervention development and feasibility trial using mixed qualitative and quantitative approach conditions: Chronic Heart Failure conditions: Frailty studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Intervention Development measure: Phase I: Qualitative evaluation with stakeholders to identify gaps in current HF care pathway leading to unmet healthcare needs in older people living with frailty and CHF measure: Phase II: Co-design and production of a holistic, patient-centered intervention addressing various healthcare needs of older people living with frailty and CHF measure: Phase IIa: Time spent in sedentary, light, moderate and vigorous activity over monitoring duration measure: Phase III: Change in physical function as assessed by the SPPB upon completion of 12-week intervention and at 6 month follow up (this may alter depending on findings from Phase II) sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Glenfield Hospital status: RECRUITING city: Leicester country: United Kingdom name: Shirley Sze role: CONTACT email: kyss1@leicester.ac.uk lat: 52.6386 lon: -1.13169 hasResults: False